Abstract
Looking for new active molecules against Mycobacterium tuberculosis, a small focused library of 1,2,3-triazoles was efficiently prepared by click chemistry. Compounds were subsequently tested against different pathogenic and opportunistic mycobacteria including M. avium and M. tuberculosis. Two of them showed MIC at lower μg/mL concentration for M. avium and even below that for M. tuberculosis, being more potent that control drugs.
Article PDF
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C (2003) Tuberculosis. Lancet 362: 887–899. doi:10.1016/S0140-6736(03)14333-4
WHO: (1993) Tuberculosis on the increase. World Health Forum 14: 1–94
Espinal MA (2003) The global situation of MDR-TB. Tuberculosis 83: 44–51. doi:10.1016/S1472-9792(02)00058-6
Afanas’ev M, Ikryannikova L, Il’ina E, Kuz’min A, Larionova E, Smirnova T, Chernousova L, Govorun V (2011) Molecular typing of Mycobacterium tuberculosis circulated in Moscow, Russian Federation. Eur J Clin Microbiol Infect Dis 30: 181–191. doi:10.1007/s10096-010-1067-z
Coker R (2001) Detention and mandatory treatment for tuberculosis patients in Russia. Lancet 358: 349–350. doi:10.1016/S0140-6736(01)05587-8
World Health Organization (2002) Global tuberculosis control: surveillance, planning, financing. WHO/CDS/TB/2002.295. World Health Organization, Geneva, Switzerland
Sepkowitz K, Raffalli J, Riley L, Kiehn T, Armstrong D (1995) Tuberculosis in the AIDS era. Clin Microbiol Rev 8: 180–199
Janin YL (2007) Antituberculosis drugs: ten years of research. Bioorg Med Chem 15: 2479–2513. doi:10.1016/j.bmc.2007.01.030
Spalding MD, Prigge ST (2010) Lipoic acid metabolism in microbial pathogens. Microbiol Mol Biol Rev 74: 200–228. doi:10.1128/MMBR.00008-10
Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77–84. doi:10.1046/j.1365-2958.2003.03425.x
Ma Q, Zhao X, Nasser Eddine A, Geerlof A, Li X, Cronan JE, Kaufmann SH, Wilmanns M (2006) The Mycobacterium tuberculosis LipB enzyme functions as a cysteine/lysine dyad acyltransferase. Proc Natl Acad Sci USA 103: 8662–8667. doi:10.1073/pnas.0510436103
Morbidoni HR, Vilcheze C, Kremer L, Bittman R, Sacchettini JC, Jacobs WR Jr (2006) Dual inhibition of mycobacterial fatty acid biosynthesis and degradation by 2-alkynoic acids. Chem Biol 13: 297–307. doi:10.1016/j.chembiol.2006.01.005
Vilcheze C, Morbidoni HR, Weisbrod TR, Iwamoto H, Kuo M, Sacchettini JC, Jacobs WR Jr (2000) Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182: 4059–4067. doi:10.1128/JB.186.13.4051-4055.2004
Lu H, Tonge PJ (2008) Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res 41: 11–20. doi:10.1021/ar700156e
Sullivan TJ, Truglio JJ, Boyne ME, Novichenok P, Zhang X, Stratton CF, Li HJ, Kaur T, Amin A, Johnson F, Slayden RA, Kisker C, Tonge PJ (2006) High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem Biol 1: 43–53. doi:10.1021/cb0500042
Rivers EC, Mancera RL (2008) New anti-tuberculosis drugs with novel mechanisms of action. Curr Med Chem 15: 1956–1967. doi:10.2174/092986708785132906
McLean KJ, Marshall KR, Richmond A, Hunter IS, Fowler K, Kieser T, Gurcha SS, Besra GS, Munro AW (2002) Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 148: 2937–2949
Ahmad Z, Sharma S, Khuller GK (2005) In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett 251: 19–22. doi:10.1016/j.femsle.2005.07.022
Ahmad Z, Sharma S, Khuller GK (2006) The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett 258: 200–203. doi:10.1111/j.1574-6968.2006.00224.x
Ahmad Z, Sharma S, Khuller GK (2006) Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett 261: 181–186. doi:10.1111/j.1574-6968.2006.00350.x
Jadhav GR, Shaikh MU, Kale RP, Shiradkar MR, Gill CH (2009) SAR study of clubbed [1,2,4]-triazolyl with fluorobenzimidazoles as antimicrobial and antituberculosis agents. Eur J Med Chem 44: 2930–2935. doi:10.1016/j.ejmech.2008.12.001
Ozdemir A, Turan-Zitouni G, Kaplancikli ZA, Chevallet P (2007) Synthesis of some 4-arylidenamino-4H-1,2,4-triazole-3-thiols and their antituberculosis activity. J Enzyme Inhib Med Chem 22: 511–516. doi:10.1080/14756360601178424
Kaplancikli ZA, Turan-Zitouni G, Chevallet P (2005) Synthesis and antituberculosis activity of new 3-alkylsulfanyl-1,2,4-triazole derivatives. J Enzyme Inhib Med Chem 20: 179–182. doi:10.1080/14756360500043471
Shiradkar MR, Murahari KK, Gangadasu HR, Suresh T, Kalyan CA, Panchal D, Kaur R, Burange P, Ghogare J, Mokale V, Raut M (2007) Synthesis of new S-derivatives of clubbed triazolyl thiazole as anti-Mycobacterium tuberculosis agents. Bioorg Med Chem 15: 3997–4008. doi:10.1016/j.bmc.2007.04.003
Dabak K, Sezer O, Akar A, Anac O (2003) Synthesis and investigation of tuberculosis inhibition activities of some 1,2,3-triazole derivatives. Eur J Med Chem 38: 215–218. doi:10.1016/S0223-5234(02)01445-9
Costa MS, Boechat N, Rangel EA, de C. da Silva F, de Souza AM, Rodrigues CR, Castro HC, Junior IN, Lourenco MC, Wardell SM, Ferreira VF (2006) Synthesis, tuberculosis inhibitory activity, and SAR study of N-substituted-phenyl-1,2,3-triazole derivatives. Bioorg Med Chem 14: 8644–8653. doi:10.1016/j.bmc.2006.08.019
Gill C, Jadhav G, Shaikh M, Kale R, Ghawalkar A, Nagargoje D, Shiradkar M (2008) Clubbed [1,2,3] triazoles by fluorine benzimidazole: a novel approach to H37Rv inhibitors as a potential treatment for tuberculosis. Bioorg Med Chem Lett 18: 6244–6247. doi:10.1016/j.bmcl.2008.09.096
Kolb HC, Sharpless KB (2003) The growing impact of click chemistry on drug discovery. Drug Discov Today 8: 1128–1137. doi:10.1016/S1359-6446(03)02933-7
Tron GC, Pirali T, Billington RA, Canonico PL, Sorba G, Genazzani AA (2008) Click chemistry reactions in medicinal chemistry: applications of the 1,3-dipolar cycloaddition between azides and alkynes. Med Res Rev 28: 278–308. doi:10.1002/med.20107
Rostovtsev VV, Green LG, Fokin VV, Sharpless KB (2002) A stepwise Hüisgen cycloaddition process: copper(I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angew Chem Int Ed Engl 41: 2596–2599. doi:10.1002/1521-3773(20020715)41:14
Lee B-Y, Park SR, Jeon HB, Kim KS (2006) A new solvent system for efficient synthesis of 1,2,3-triazoles. Tetrahedron Lett 47: 5105–5109. doi:10.1016/j.tetlet.2006.05.079
Angelo NG, Arora PS (2007) Solution- and solid-phase synthesis of triazole oligomers that display protein-like functionality. J Org Chem 72: 7963–7967. doi:10.1021/jo701292h
VijayaRaghava Reddy L, Venkat Reddy P, Mishra NN, Shukla PK, Yadav G, Srivastava R, Shaw AK (2010) Synthesis and biological evaluation of glycal-derived novel tetrahydrofuran 1,2,3-triazoles by ‘click’ chemistry. Carbohydr Res 345: 1515–1521. doi:10.1016/j.carres.2010.03.031
Jlalia I, Beauvineau C, Beauvière S, Önen E, Aufort M, Beauvineau A, Khaba E, Herscovici J, Meganem F, Girard C (2010) Automated synthesis of a 96 product-sized library of triazole derivatives using a solid phase supported copper catalyst. Molecules 15: 3087–3120. doi:10.3390/molecules15053087
Turner RA, Oliver AG, Lokey RS (2007) Click chemistry as a macrocyclization tool in the solid-phase synthesis of small cyclic peptides. Org Lett 9: 5011–5014. doi:10.1021/ol702228u
Colombano G, Travelli C, Galli U, Caldarelli A, Chini MG, Canonico PL, Sorba G, Bifulco G, Tron GC, Genazzani AA (2009) A novel potent nicotinamide phosphoribosyltransferase inhibitor synthesized via click chemistry. J Med Chem 53: 616–623. doi:10.1021/jm9010669
Jia Z, Zhu Q (2010) ‘Click’ assembly of selective inhibitors for MAO-A. Bioorg Med Chem Lett 20: 6222–6225. doi:10.1016/j.bmcl.2010.08.104
Choi KW, Brimble MA (2008) Synthesis of spiroacetal-triazoles as privileged natural product-like scaffolds using “click chemistry”. Org Biomol Chem 6: 3518–3526. doi:10.1039/b808454h
Bagwell CL, Moloney MG, Yaqoob M (2010) Oxazolomycins: natural product lead structures for novel antibacterials by click fragment conjugation. Bioorg Med Chem Lett 20: 2090–2094. doi:10.1016/j.bmcl.2010.02.066
Philalay JS, Palermo CO, Hauge KA, Rustad TR, Cangelosi GA (2004) Genes required for intrinsic multidrug resistance in Mycobacterium avium. Antimicrob Agents Chemother 48: 3412–3418. doi:10.1128/AAC.48.9.3412-3418.2004
Barry CE III, Slayden RA, Sampson AE, Lee RE (2000) Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. Biochem Pharmacol 59: 221–231. doi:10.1016/S0006-2952(99)00253-1
Prado S, Ledeit H, Michel S, Koch M, Darbord JC, Cole ST, Tillequin F, Brodin P (2006) Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. Bioorg Med Chem 14: 5423–5428. doi:10.1016/j.bmc.2006.03.033
Appukkuttan P, Dehaen W, Fokin VV, Van der Eycken E (2004) A microwave-assisted click chemistry synthesis of 1,4-disubstituted 1,2,3-triazoles via a copper(I)-catalyzed three-component reaction. Org Lett 6: 4223–4225. doi:10.1021/ol048341v
Babich H, Borenfreund E (1991) Cytotoxicity of T-2 toxin and its metabolites determined with the neutral red cell viability assay. Appl Environ Microbiol 57: 2101–2103
Author information
Authors and Affiliations
Corresponding author
Electronic Supplementary Material
The Below is the Electronic Supplementary Material.
Rights and permissions
About this article
Cite this article
Labadie, G.R., de la Iglesia, A. & Morbidoni, H.R. Targeting tuberculosis through a small focused library of 1,2,3-triazoles. Mol Divers 15, 1017–1024 (2011). https://doi.org/10.1007/s11030-011-9319-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11030-011-9319-0